Indeed, current data assume that MSH2, MLH1, and EpCAM mutation carriers have 13% of cumulative risk incidence of developing gastric tumors at an age of 75 years; however, MSH6 carriers have only 3% of the risk [27]. Here, MSH2 is linked to gastric neoplasm.